Role of tertiary lymphoid structures (TLS) in anti-tumor immunity: Potential tumor-induced cytokines/chemokines that regulate TLS formation in epithelial-derived cancers

Cancers

Volumn 6, Issue 2, 2014, Pages 969-997

  Pimenta, Erica M ^a   Barnes, Betsy J ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Anti tumor immunity; B cells; CXCL13; Germinal center; Humoral immunity; T cells; Tertiary lymphoid structure

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; OSTEOCLAST DIFFERENTIATION FACTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE;

B LYMPHOCYTE; BREAST CANCER; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CANCER; EPITHELIUM CELL; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOGENICITY; LUNG CANCER; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; TERTIARY LYMPHOID STRUCTURE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; VDJ RECOMBINATION;

EID: 84899415945     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6020969     Document Type: Review

References (142)

1. Neyt, K.; Perros, F.; GeurtsvanKessel, C.H.; Hammad, H.; Lambrecht, B.N. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012, 33, 297-305.
2. Carragher, D.M.; Rangel-Moreno, J.; Randall, T.D. Ectopic lymphoid tissues and local immunity. Sem. Immunol. 2008, 20, 26-42.
3. Willard-Mack, C.L. Normal structure, function, and histology of lymph nodes. Toxicol. Pathol. 2006, 34, 409-424.
4. Blum, K.S.; Pabst, R. Keystones in lymph node development. J. Anat. 2006, 209, 585-595.
5. Aloisi, F.; Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 2006, 6, 205-217.
6. Muniz, L.R.; Pacer, M.E.; Lira, S.A.; Furtado, G.C. A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J. Immunol. 2011, 187, 828-834.
7. Rupprecht, T.A.; Plate, A.; Adam, M.; Wick, M.; Kastenbauer, S.; Schmidt, C.; Klein, M.; Pfister, H.W.; Koedel, U. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute lyme neuroborreliosis. J. Neuroinflamm. 2009, 6.doi:10.1186/1742-2094-6-42.
8. Cassier, P.A.; Treilleux, I.; Bachelot, T.; Ray-Coquard, I.; Bendriss-Vermare, N.; Menetrier-Caux, C.; Tredan, O.; Goddard-Leon, S.; Pin, J.J.; Mignotte, H., et al. Prognostic value of the expression of c-chemokine receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer 2011, 11, doi:10.1186/1471-2407-11-213.
9. Luther, S.A.; Bidgol, A.; Hargreaves, D.C.; Schmidt, A.; Xu, Y.; Paniyadi, J.; Matloubian, M.; Cyster, J.G. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 2002, 169, 424-433.
10. Ohmatsu, H.; Sugaya, M.; Kadono, T.; Tamaki, K. CXCL13 and CCL21 are expressed in ectopic lymphoid follicles in cutaneous lymphoproliferative disorders. J. Investig. Dermatol. 2007, 127, 2466-2468.
11. Mumtaz, M.; Wagsater, D.; Lofgren, S.; Hugander, A.; Zar, N.; Dimberg, J. Decreased expression of the chemokine CCL21 in human colorectal adenocarcinomas. Oncol. Rep. 2009, 21, 153-158.
12. Novak, L.; Igoucheva, O.; Cho, S.; Alexeev, V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol. Cancer Ther. 2007, 6, 1755-1764.
13. Christopherson, K.W., 2nd; Campbell, J.J.; Hromas, R.A. Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration. Blood 2001, 98, 3562-3568.
14. Kar, U.K.; Srivastava, M.K.; Andersson, A.; Baratelli, F.; Huang, M.; Kickhoefer, V.A.; Dubinett, S.M.; Rome, L.H.; Sharma, S. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One 2011, 6, e18758.
15. Ashour, A.E.; Turnquist, H.R.; Singh, R.K.; Talmadge, J.E.; Solheim, J.C. CCL21-induced immune cell infiltration. Int. Immunopharmacol. 2007, 7, 272-276.
16. Slight, S.R.; Rangel-Moreno, J.; Gopal, R.; Lin, Y.; Fallert Junecko, B.A.; Mehra, S.; Selman, M.; Becerril-Villanueva, E.; Baquera-Heredia, J.; Pavon, L., et al. CXCR5+ T helper cells mediate protective immunity against tuberculosis. J. Clin. Investig. 2013, 123, 712-726.
17. Cipponi, A.; Mercier, M.; Seremet, T.; Baurain, J.F.; Theate, I.; van den Oord, J.; Stas, M.; Boon, T.; Coulie, P.G.; van Baren, N. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012, 72, 3997-4007.
18. Morita, R.; Schmitt, N.; Bentebibel, S.E.; Ranganathan, R.; Bourdery, L.; Zurawski, G.; Foucat, E.; Dullaers, M.; Oh, S.; Sabzghabaei, N., et al. Human blood CXCR5+CD4+ T cells are counterparts of t follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011, 34, 108-121.
19. Chevalier, N.; Jarrossay, D.; Ho, E.; Avery, D.T.; Ma, C.S.; Yu, D.; Sallusto, F.; Tangye, S.G.; Mackay, C.R. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J. Immunol. 2011, 186, 5556-5568.
20. Singh, P.; Coskun, Z.Z.; Goode, C.; Dean, A.; Thompson-Snipes, L.; Darlington, G. Lymphoid neogenesis and immune infiltration in aged liver. Hepatology 2008, 47, 1680-1690.
21. Gunther, J.; Koczan, D.; Yang, W.; Nurnberg, G.; Repsilber, D.; Schuberth, H.J.; Park, Z.; Maqbool, N.; Molenaar, A.; Seyfert, H.M. Assessment of the immune capacity of mammary epithelial cells: Comparison with mammary tissue after challenge with Escherichia coli. Vet. Res. 2009, 40, e31.
22. Panse, J.; Friedrichs, K.; Marx, A.; Hildebrandt, Y.; Luetkens, T.; Barrels, K.; Horn, C.; Stahl, T.; Cao, Y.; Milde-Langosch, K., et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br. J. Cancer 2008, 99, 930-938.
23. Carlsen, H.S.; Baekkevold, E.S.; Johansen, F.E.; Haraldsen, G.; Brandtzaeg, P. B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue. Gut 2002, 51, 364-371.
24. Salomonsson, S.; Larsson, P.; Tengner, P.; Mellquist, E.; Hjelmstrom, P.; Wahren-Herlenius, M. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease sjogren's syndrome. Scand. J. Immunol. 2002, 55, 336-342.
25. Jiang, J.; Karimi, O.; Ouburg, S.; Champion, C.I.; Khurana, A.; Liu, G.; Freed, A.; Pleijster, J.; Rozengurt, N.; Land, J.A., et al. Interruption of CXCL13-CXCR5 axis increases upper genital tract pathology and activation of NKT cells following chlamydial genital infection. PLoS One 2012, 7, e47487.
26. Pickens, S.R.; Chamberlain, N.D.; Volin, M.V.; Pope, R.M.; Talarico, N.E.; Mandelin, A.M., 2nd; Shahrara, S. Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis. Arthr. Rheum. 2012, 64, 2471-2481.
27. Degli-Esposti, M.A.; Davis-Smith, T.; Din, W.S.; Smolak, P.J.; Goodwin, R.G.; Smith, C.A. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. J. Immunol. 1997, 158, 1756-1762.
28. Coelho, F.M.; Natale, D.; Soriano, S.F.; Hons, M.; Swoger, J.; Mayer, J.; Danuser, R.; Scandella, E.; Pieczyk, M.; Zerwes, H.G., et al. Naive B-cell trafficking is shaped by local chemokine availability and LFA-1-independent stromal interactions. Blood 2013, 121, 4101-4109.
29. Leon, B.; Ballesteros-Tato, A.; Browning, J.L.; Dunn, R.; Randall, T.D.; Lund, F.E. Regulation of TH2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. Nat. Immunol. 2012, 13, 681-690.
30. Nelson, B.H. CD20+ B cells: The other tumor-infiltrating lymphocytes. J. Immunol. 2010, 185, 4977-4982.
31. De Guinoa, J.S.; Barrio, L.; Mellado, M.; Carrasco, Y.R. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood 2011, 118, 1560-1569.
32. Spaner, D.; Bahlo, A. B Lymphocytes in Cancer Immunology. In Experimental and Applied Immunotherapy; Medin, J., Fowler, D., Eds.; Humana Press: New York, NY, USA, 2011; pp. 37-57.
33. Liu, X.; Nurieva, R.I.; Dong, C. Transcriptional regulation of follicular T-helper (TFH) cells. Immunol. Rev. 2013, 252, 139-145.
34. Smedbakken, L.M.; Halvorsen, B.; Daissormont, I.; Ranheim, T.; Michelsen, A.E.; Skjelland, M.; Sagen, E.L.; Folkersen, L.; Krohg-Sorensen, K.; Russell, D., et al. Increased levels of the homeostatic chemokine CXCL13 in human atherosclerosis-potential role in plaque stabilization. Atherosclerosis 2012, 224, 266-273.
35. Coronella-Wood, J.A.; Hersh, E.M. Naturally occurring B-cell responses to breast cancer. Cancer Immunol. Immunother. 2003, 52, 715-738.
36. Murphy, M.A.; O'Leary, J.J.; Cahill, D.J. Assessment of the humoral immune response to cancer. J. Proteom. 2012, 75, 4573-4579.
37. Penn, I.; Starzl, T.E. Immunosuppression and cancer. Transpl. Proc. 1973, 5, 943-947.
38. Bergomas, F.; Grizzi, F.; Doni, A.; Pesce, S.; Laghi, L.; Allavena, P.; Mantovani, A.; Marchesi, F. Tertiary intratumor lymphoid tissue in colo-rectal cancer. Cancers 2011, 4, 1-10.
39. Gu-Trantien, C.; Loi, S.; Garaud, S.; Equeter, C.; Libin, M.; de Wind, A.; Ravoet, M.; le Buanec, H.; Sibille, C.; Manfouo-Foutsop, G., et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Investig. 2013, 123, 2873-2892.
40. Coppola, D.; Nebozhyn, M.; Khalil, F.; Dai, H.; Yeatman, T.; Loboda, A.; Mule, J.J. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 2011, 179, 37-45.
41. Messina, J.L.; Fenstermacher, D.A.; Eschrich, S.; Qu, X.; Berglund, A.E.; Lloyd, M.C.; Schell, M.J.; Sondak, V.K.; Weber, J.S.; Mule, J.J. 12-chemokine gene signature identifies lymph node-like structures in melanoma: Potential for patient selection for immunotherapy? Sci. Rep. 2012, 2, doi:10.1038/srep00765.
42. Gottlin, E.B.; Bentley, R.C.; Campa, M.J.; Pisetsky, D.S.; Herndon, J.E., 2nd; Patz, E.F., Jr. The association of intratumoral germinal centers with early-stage non-small cell lung cancer. J. Thoracic Oncol. 2011, 6, 1687-1690.
43. Goc, J.; Fridman, W.H.; Sautes-Fridman, C.; Dieu-Nosjean, M.C. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013, 2, e26836.
44. Denkert, C.; Loibl, S.; Noske, A.; Roller, M.; Muller, B.M.; Komor, M.; Budczies, J.; Darb-Esfahani, S.; Kronenwett, R.; Hanusch, C., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010, 28, 105-113.
45. Nzula, S.; Going, J.J.; Stott, D.I. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 2003, 63, 3275-3280.
46. Alexe, G.; Dalgin, G.S.; Scanfeld, D.; Tamayo, P.; Mesirov, J.P.; DeLisi, C.; Harris, L.; Barnard, N.; Martel, M.; Levine, A.J., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007, 67, 10669-10676.
47. Krell, J.; Frampton, A.E.; Stebbing, J. The clinical significance of tumor infiltrating lymphoctyes in breast cancer: Does subtype matter? BMC Cancer 2012, 12, e135.
48. Coronella, J.A.; Spier, C.; Welch, M.; Trevor, K.T.; Stopeck, A.T.; Villar, H.; Hersh, E.M. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J. Immunol. 2002, 169, 1829-1836.
49. Mahmoud, S.M.; Lee, A.H.; Paish, E.C.; Macmillan, R.D.; Ellis, I.O.; Green, A.R. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res. Treat. 2012, 132, 545-553.
50. Schmidt, M.; Bohm, D.; von Torne, C.; Steiner, E.; Puhl, A.; Pilch, H.; Lehr, H.A.; Hengstler, J.G.; Kolbl, H.; Gehrmann, M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68, 5405-5413.
51. Hansen, M.H.; Nielsen, H.; Ditzel, H.J. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc. Natl. Acad. Sci. USA 2001, 98, 12659-12664.
52. Pavoni, E.; Monteriu, G.; Santapaola, D.; Petronzelli, F.; Anastasi, A.M.; Pelliccia, A.; D'Alessio, V.; de Santis, R.; Minenkova, O. Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol. 2007, 7, e70.
53. Lu, H.; Goodell, V.; Disis, M.L. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J. Proteome Res. 2008, 7, 1388-1394.
54. Fischer, E.; Kobold, S.; Kleber, S.; Kubuschok, B.; Braziulis, E.; Knuth, A.; Renner, C.; Wadle, A. Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J. Immunol. 2010, 185, 3095-3102.
55. Martinet, L.; Garrido, I.; Filleron, T.; le Guellec, S.; Bellard, E.; Fournie, J.J.; Rochaix, P.; Girard, J.P. Human solid tumors contain high endothelial venules: Association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011, 71, 5678-5687.
56. Liu, W.; Peng, Y.; Tobin, D.J. A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis. Peer J. 2013, 1, e49.
57. Pimenta, E.M.; De, S.; Feng, D.; Hall, K.; Ran, S.; Barnes, B.J. Rutgers Biomedical and Health Sciences, New Jersey Medical School-Cancer Center, Newark, NJ, USA. Unpublished work, 2014.
58. Biswas, S.K.; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 2010, 11, 889-896.
59. Wu, S.; Lu, X.; Zhang, Z.L.; Lei, P.; Hu, P.; Wang, M.; Huang, B.; Xing, W.; Jiang, X.T.; Liu, H.J., et al. CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2. Carcinogenesis 2011, 32, 296-304.
60. Kim, S.J.; Shin, J.Y.; Lee, K.D.; Bae, Y.K.; Sung, K.W.; Nam, S.J.; Chun, K.H. Microrna let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 2012, 14, R14.
61. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
62. Nguyen-Hoai, T.; Baldenhofer, G.; Ahmed, M.S.; Pham-Duc, M.; Gries, M.; Lipp, M.; Dorken, B.; Pezzutto, A.; Westermann, J. CCL19 (ELC) improves Th1-polarized immune responses and protective immunity in a murine HER2/neu DNA vaccination model. J. Gene Med. 2012, 14, 128-137.
63. Nguyen-Hoai, T.; Hohn, O.; Vu, M.D.; Baldenhofer, G.; Ahmed, M.S.S.; Dorken, B.; Norley, S.; Lipp, M.; Pezzutto, A.; Westermann, J. Ccl19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: Improved vaccine efficacy and a role for B cells as APC. Cancer Gene Ther. 2012, 19, 880-887.
64. Marisa, L.; de Reynies, A.; Duval, A.; Selves, J.; Gaub, M.P.; Vescovo, L.; Etienne-Grimaldi, M.C.; Schiappa, R.; Guenot, D.; Ayadi, M., et al. Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Med. 2013, 10, e1001453.
65. Curtis, N.J.; Primrose, J.N.; Thomas, G.J.; Mirnezami, A.H.; Ottensmeier, C.H. The adaptive immune response to colorectal cancer: From the laboratory to clinical practice. Eur. J. Surg. Oncol. 2012, 38, 889-896.
66. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
67. Camus, M.; Tosolini, M.; Mlecnik, B.; Pages, F.; Kirilovsky, A.; Berger, A.; Costes, A.; Bindea, G.; Charoentong, P.; Bruneval, P., et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009, 69, 2685-2693.
68. Yoon, H.H.; Orrock, J.M.; Foster, N.R.; Sargent, D.J.; Smyrk, T.C.; Sinicrope, F.A. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One 2012, 7, e42274.
69. Xu, Y.; Xu, Q.; Yang, L.; Liu, F.; Ye, X.; Wu, F.; Ni, S.; Tan, C.; Cai, G.; Meng, X., et al. Gene expression analysis of peripheral blood cells reveals toll-like receptor pathway deregulation in colorectal cancer. PLoS One 2013, 8, e62870.
70. Kirman, I.; Huang, E.H.; Whelan, R.L. B cell response to tumor antigens is associated with depletion of b progenitors in murine colocarcinoma. Surgery 2004, 135, 313-318.
71. Maletzki, C.; Jahnke, A.; Ostwald, C.; Klar, E.; Prall, F.; Linnebacher, M. Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS One 2012, 7, e32639.
72. Li, J.; O'Malley, M.; Sampath, P.; Kalinski, P.; Bartlett, D.L.; Thorne, S.H. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia 2012, 14, 1115-1121.
73. Wong, K.L.; Tai, J.J.; Wong, W.C.; Han, H.; Sem, X.; Yeap, W.H.; Kourilsky, P.; Wong, S.C. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011, 118, e16-e31.
74. Di Caro, G.; Bergomas, F.; Grizzi, F.; Doni, A.; Bianchi, P.; Malesci, A.; Laghi, L.; Allavena, P.; Mantovani, A.; Marchesi, F. Occurrence of tertiary lymphoid tissue is associated to T cell infiltration and predicts better prognosis in early stage colorectal cancers. Clin. Cancer Res. 2014, doi:10.1158/1078-0432.CCR-13-2590.
75. Jonsson, G.; Busch, C.; Knappskog, S.; Geisler, J.; Miletic, H.; Ringner, M.; Lillehaug, J.R.; Borg, A.; Lonning, P.E. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 2010, 16, 3356-3367.
76. Dobner, B.C.; Riechardt, A.I.; Joussen, A.M.; Englert, S.; Bechrakis, N.E. Expression of haematogenous and lymphogenous chemokine receptors and their ligands on uveal melanoma in association with liver metastasis. Acta Ophthalmol. 2012, 90, e638-e644.
77. Charest-Morin, X.; Pepin, R.; Gagne-Henley, A.; Morissette, G.; Lodge, R.; Marceau, F. C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells. Front. Pharmacol. 2013, 4, doi:10.3389/fphar.2013.00122.
78. Dhawan, P.; Su, Y.; Thu, Y.M.; Yu, Y.; Baugher, P.; Ellis, D.L.; Sobolik-Delmaire, T.; Kelley, M.; Cheung, T.C.; Ware, C.F., et al. The lymphotoxin-beta receptor is an upstream activator of NF-κb-mediated transcription in melanoma cells. J. Biol. Chem. 2008, 283, 15399-15408.
79. Schrama, D.; Straten, P.T.; Fischer, W.H.; McLellan, A.D.; Brocker, E.B.; Reisfeld, R.A.; Becker, J.C. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001, 14, 111-121.
80. Wang, E.; Miller, L.D.; Ohnmacht, G.A.; Mocellin, S.; Perez-Diez, A.; Petersen, D.; Zhao, Y.; Simon, R.; Powell, J.I.; Asaki, E., et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002, 62, 3581-3586.
81. DiLillo, D.J.; Yanaba, K.; Tedder, T.F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 2010, 184, 4006-4016.
82. Ladanyi, A.; Kiss, J.; Mohos, A.; Somlai, B.; Liszkay, G.; Gilde, K.; Fejos, Z.; Gaudi, I.; Dobos, J.; Timar, J. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol. Immunother. 2011, 60, 1729-1738.
83. Rohrbeck, A.; Neukirchen, J.; Rosskopf, M.; Pardillos, G.G.; Geddert, H.; Schwalen, A.; Gabbert, H.E.; von Haeseler, A.; Pitschke, G.; Schott, M., et al. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J. Transl. Med. 2008, 6, doi:10.1186/1479-5876-6-69.
84. Kalari, K.R.; Rossell, D.; Necela, B.M.; Asmann, Y.W.; Nair, A.; Baheti, S.; Kachergus, J.M.; Younkin, C.S.; Baker, T.; Carr, J.M., et al. Deep sequence analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations. Front. Oncol. 2012, 2, doi:10.3389/fonc.2012.00012.
85. Botling, J.; Edlund, K.; Lohr, M.; Hellwig, B.; Holmberg, L.; Lambe, M.; Berglund, A.; Ekman, S.; Bergqvist, M.; Ponten, F., et al. Biomarker discovery in non-small cell lung cancer: Integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin. Cancer Res. 2013, 19, 194-204.
86. Roepman, P.; Jassem, J.; Smit, E.F.; Muley, T.; Niklinski, J.; van de Velde, T.; Witteveen, A.T.; Rzyman, W.; Floore, A.; Burgers, S., et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin. Cancer Res. 2009, 15, 284-290.
87. De Chaisemartin, L.; Goc, J.; Damotte, D.; Validire, P.; Magdeleinat, P.; Alifano, M.; Cremer, I.; Fridman, W.H.; Sautes-Fridman, C.; Dieu-Nosjean, M.C. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011, 71, 6391-6399.
88. Hillinger, S.; Yang, S.C.; Batra, R.K.; Strieter, R.M.; Weder, W.; Dubinett, S.M.; Sharma, S. CCL19 reduces tumour burden in a model of advanced lung cancer. Br. J. Cancer 2006, 94, 1029-1034.
89. Cardell, M.; Arni, S.; Yang, S.-C.; Korom, S.; Opitz, I.; Lardinois, D.; Sharma, S.; Dubinett, S.M.; Weder, W.; Hillinger, S. Combined CCL19/IL-7 treatment eradicates tumors in murine models of lung cancer. AACR Meet. Abstr. 2006, 2006, Abstract No. 5557.
90. Zhang, Q.; Sun, L.; Yin, L.; Ming, J.; Zhang, S.; Luo, W.; Qiu, X. CCL19/CCR7 upregulates heparanase via specificity protein-1 (SP1) to promote invasion of cell in lung cancer. Tumour Biol. 2013, 34, 2703-2708.
91. Riedl, K.; Baratelli, F.; Batra, R.K.; Yang, S.C.; Luo, J.; Escuadro, B.; Figlin, R.; Strieter, R.; Sharma, S.; Dubinett, S. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol. Cancer 2003, 2.doi:10.1186/1476-4598-2-35.
92. Dieu-Nosjean, M.C.; Antoine, M.; Danel, C.; Heudes, D.; Wislez, M.; Poulot, V.; Rabbe, N.; Laurans, L.; Tartour, E.; de Chaisemartin, L., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26, 4410-4417.
93. Remark, R.; Alifano, M.; Cremer, I.; Lupo, A.; Dieu-Nosjean, M.C.; Riquet, M.; Crozet, L.; Ouakrim, H.; Goc, J.; Cazes, A., et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin. Clin. Cancer Res. 2013, 19, 4079-4091.
94. Goc, J.; Germain, C.; Vo-Bourgais, T.K.; Lupo, A.; Klein, C.; Knockaert, S.; de Chaisemartin, L.; Ouakrim, H.; Becht, E.; Alifano, M., et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014, 74, 705-715.
95. Hopewell, E.L.; Zhao, W.; Fulp, W.J.; Bronk, C.C.; Lopez, A.S.; Massengill, M.; Antonia, S.; Celis, E.; Haura, E.B.; Enkemann, S.A., et al. Lung tumor NF-kappaB signaling promotes T cell-mediated immune surveillance. J. Clin. Investig. 2013, 123, 2509-2522.
96. Lohr, M.; Edlund, K.; Botling, J.; Hammad, S.; Hellwig, B.; Othman, A.; Berglund, A.; Lambe, M.; Holmberg, L.; Ekman, S., et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013, 333, 222-228.
97. Reuschenbach, M.; von Knebel Doeberitz, M.; Wentzensen, N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother. 2009, 58, 1535-1544.
98. + T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 2012, 18, 3281-3292.
99. Huang, Y.; Yu, X.; Wang, L.; Zhou, S.; Sun, J.; Feng, N.; Nie, S.; Wu, J.; Gao, F.; Fei, B., et al. Four genetic polymorphisms of lymphotoxin-alpha gene and cancer risk: A systematic review and meta-analysis. PLoS One 2013, 8, e82519.
100. Takei, K.; Ikeda, S.; Arai, T.; Tanaka, N.; Muramatsu, M.; Sawabe, M. Lymphotoxin-alpha polymorphisms and presence of cancer in 1536 consecutive autopsy cases. BMC Cancer 2008, 8, doi:10.1186/1471-2407-8-235.
101. Drutskaya, M.S.; Efimov, G.A.; Kruglov, A.A.; Kuprash, D.V.; Nedospasov, S.A. Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life 2010, 62, 283-289.
102. Hamanishi, J.; Mandai, M.; Matsumura, N.; Baba, T.; Yamaguchi, K.; Fujii, S.; Konishi, I. Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells 2010, 28, 164-173.
103. Turnquist, H.R.; Lin, X.; Ashour, A.E.; Hollingsworth, M.A.; Singh, R.K.; Talmadge, J.E.; Solheim, J.C. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int. J. Oncol. 2007, 30, 631-639.
104. Hwang, T.L.; Lee, L.Y.; Wang, C.C.; Liang, Y.; Huang, S.F.; Wu, C.M. CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J. Gastroenterol. 2012, 18, 1249-1256.
105. Yuvaraj, S.; Griffin, A.C.; Sundaram, K.; Kirkwood, K.L.; Norris, J.S.; Reddy, S.V. A novel function of CXCL13 to stimulate rank ligand expression in oral squamous cell carcinoma cells. Mol. Cancer Res. 2009, 7, 1399-1407.
106. Sambandam, Y.; Sundaram, K.; Liu, A.; Kirkwood, K.L.; Ries, W.L.; Reddy, S.V. CXCL13 activation of c-Myc induces rank ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene 2013, 32, 97-105.
107. Pandruvada, S.N.; Yuvaraj, S.; Liu, X.; Sundaram, K.; Shanmugarajan, S.; Ries, W.L.; Norris, J.S.; London, S.D.; Reddy, S.V. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int. J. Cancer 2010, 126, 2319-2329.
108. Maleki, S.; Schlecht, N.F.; Keller, C.; Diaz, J.; Moss, J.; Prystowsky, M.B.; Macian, F.; Brandwein-Gensler, M. Lymphocytic host response to oral squamous cell carcinoma: An adaptive T-cell response at the tumor interface. Head Neck Pathol. 2011, 5, 117-122.
109. Hess, E.; Duheron, V.; Decossas, M.; Lezot, F.; Berdal, A.; Chea, S.; Golub, R.; Bosisio, M.R.; Bridal, S.L.; Choi, Y., et al. Rankl induces organized lymph node growth by stromal cell proliferation. J. Immunol. 2012, 188, 1245-1254.
110. Dougall, W.C.; Glaccum, M.; Charrier, K.; Rohrbach, K.; Brasel, K.; de Smedt, T.; Daro, E.; Smith, J.; Tometsko, M.E.; Maliszewski, C.R., et al. Rank is essential for osteoclast and lymph node development. Genes Dev. 1999, 13, 2412-2424.
111. Schramek, D.; Sigl, V.; Penninger, J.M. Rankl and rank in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol. Metab. 2011, 22, 188-194.
112. Azim, H.; Azim, H.A., Jr. Targeting RANKL in breast cancer: Bone metastasis and beyond. Exp. Rev. Anticancer Ther. 2013, 13, 195-201.
113. Pietila, T.E.; Veckman, V.; Lehtonen, A.; Lin, R.; Hiscott, J.; Julkunen, I. Multiple NF-κb and ifn regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells. J. Immunol. 2007, 178, 253-261.
114. Subrata, L.S.; Lowes, K.N.; Olynyk, J.K.; Yeoh, G.C.; Quail, E.A.; Abraham, L.J. Hepatic expression of the tumor necrosis factor family member lymphotoxin-beta is regulated by interleukin (IL)-6 and IL-1β: Transcriptional control mechanisms in oval cells and hepatoma cell lines. Liver Int. 2005, 25, 633-646.
115. Britanova, L.V.; Kuprash, D.V. New putative control elements in the promoter of CXCL13 chemokine gene, a target of alternative NF-κb pathway. Mol. Biol. 2009, 43, 657-665.
116. Moreth, K.; Brodbeck, R.; Babelova, A.; Gretz, N.; Spieker, T.; Zeng-Brouwers, J.; Pfeilschifter, J.; Young, M.F.; Schaefer, R.M.; Schaefer, L. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J. Clin. Investig. 2010, 120, 4251-4272.
117. Oeckinghaus, A.; Ghosh, S. The NF-κb family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 2009, 1, a000034.
118. Karin, M.; Lin, A. NF-κb at the crossroads of life and death. Nat. Immunol. 2002, 3, 221-227.
119. Li, C.W.; Xia, W.; Huo, L.; Lim, S.O.; Wu, Y.; Hsu, J.L.; Chao, C.H.; Yamaguchi, H.; Yang, N.K.; Ding, Q. et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-κb-mediated transcriptional upregulation of twist1. Cancer Res. 2012, 72, 1290-1300.
120. Hoesel, B.; Schmid, J.A. The complexity of NF-κb signaling in inflammation and cancer. Mol. Cancer 2013, 12, doi:10.1186/1476-4598-12-86.
121. Miyagaki, T.; Sugaya, M.; Okochi, H.; Asano, Y.; Tada, Y.; Kadono, T.; Blauvelt, A.; Tamaki, K.; Sato, S. Blocking mapk signaling downregulates CCL21 in lymphatic endothelial cells and impairs contact hypersensitivity responses. J. Investig. Dermatol. 2011, 131, 1927-1935.
122. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9, 798-809.
123. Furqan, M.; Akinleye, A.; Mukhi, N.; Mittal, V.; Chen, Y.; Liu, D. STAT inhibitors for cancer therapy. J. Hematol. Oncol. 2013, 6, 90.
124. Barton, B.E.; Murphy, T.F.; Shu, P.; Huang, H.F.; Meyenhofer, M.; Barton, A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Ther. 2004, 3, 1183-1191.
125. Barton, B.E.; Karras, J.G.; Murphy, T.F.; Barton, A.; Huang, H.F. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. 2004, 3, 11-20.
126. Widschwendter, A.; Tonko-Geymayer, S.; Welte, T.; Daxenbichler, G.; Marth, C.; Doppler, W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res. 2002, 8, 3065-3074.
127. Soliman, H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control 2013, 20, 17-21.
128. Bidwell, B.N.; Slaney, C.Y.; Withana, N.P.; Forster, S.; Cao, Y.; Loi, S.; Andrews, D.; Mikeska, T.; Mangan, N.E.; Samarajiwa, S.A., et al. Silencing of IRF7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 2012, doi:10.1038/nm.2830.
129. Bi, X.; Hameed, M.; Mirani, N.; Pimenta, E.M.; Anari, J.; Barnes, B.J. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 2011, 13, R111.
130. Li, Q.; Tainsky, M.A. Epigenetic silencing of Irf7 and/or Irf5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One 2011, 6, e28683.
131. Uccellini, L.; De Giorgi, V.; Zhao, Y.; Tumaini, B.; Erdenebileg, N.; Dudley, M.E.; Tomei, S.; Bedognetti, D.; Ascierto, M.L.; Liu, Q., et al. IRF5 gene polymorphisms in melanoma. J. Transl. Med. 2012, 10, doi:10.1186/1479-5876-10-170.
132. Bi, X.; Feng, D.; Korczeniewska, J.; Alper, N.; Hu, G.; Barnes, B.J. Deletion of IRF5 protects hematopoietic stem cells from DNA damage-induced apoptosis and suppresses gamma-irradiation-induced thymic lymphomagenesis. Oncogene 2013, doi:10.1038/onc.2013.295.
133. Hu, G.; Barnes, B.J. Irf-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J. Biol. Chem. 2009, 284, 2767-2777.
134. Hu, G.; Mancl, M.E.; Barnes, B.J. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res. 2005, 65, 7403-7412.
135. Tamura, T.; Ishihara, M.; Lamphier, M.S.; Tanaka, N.; Oishi, I.; Aizawa, S.; Matsuyama, T.; Mak, T.W.; Taki, S.; Taniguchi, T. An Irf-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995, 376, 596-599.
136. Mancl, M.E.; Hu, G.; Sangster-Guity, N.; Olshalsky, S.L.; Hoops, K.; Fitzgerald-Bocarsly, P.; Pitha, P.M.; Pinder, K.; Barnes, B.J. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J. Biol. Chem. 2005, 280, 21078-21090.
137. Sato, M.; Hata, N.; Asagiri, M.; Nakaya, T.; Taniguchi, T.; Tanaka, N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 1998, 441, 106-110.
138. Lu, R.; Moore, P.A.; Pitha, P.M. Stimulation of IRF-7 gene expression by tumor necrosis factor alpha: Requirement for NF-κB transcription factor and gene accessibility. J. Biol. Chem. 2002, 277, 16592-16598.
139. Ishibashi, D.; Atarashi, R.; Fuse, T.; Nakagaki, T.; Yamaguchi, N.; Satoh, K.; Honda, K.; Nishida, N. Protective role of interferon regulatory factor 3-mediated signaling against prion infection. J. Virol. 2012, 86, 4947-4955.
140. Shiao, S.L.; Ganesan, A.P.; Rugo, H.S.; Coussens, L.M. Immune microenvironments in solid tumors: New targets for therapy. Genes Dev. 2011, 25, 2559-2572.
141. Fox, B.A.; Schendel, D.J.; Butterfield, L.H.; Aamdal, S.; Allison, J.P.; Ascierto, P.A.; Atkins, M.B.; Bartunkova, J.; Bergmann, L.; Berinstein, N., et al. Defining the critical hurdles in cancer immunotherapy. J. Transl. Med. 2011, 9, e214.
142. Kossenkov, A.V.; Dawany, N.; Evans, T.L.; Kucharczuk, J.C.; Albelda, S.M.; Showe, L.C.; Showe, M.K.; Vachani, A. Peripheral immune cell gene expression predicts survival of patients with non-small cell lung cancer. PLoS One 2012, 7, e34392.